Prospective, Multicenter, Non-interventional Study to Characterize Profile of Patient With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PROUST
- Sponsors Janssen-Cilag
- 31 Oct 2019 Planned primary completion date changed from 30 Oct 2019 to 4 Apr 2020.
- 03 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 16 May 2019 Planned End Date changed from 31 Dec 2019 to 30 Apr 2020.